Loading patent…
AssigneesMnemo Therapeutics, Institut Curie, Institut National de la Sante et de la Recherche Medicale
InventorsMichael SAITAKIS, Sebastian AMIGORENA, Jaime Rodrigo FUENTEALBA, Sheila LOPEZ COBO, Marion ALCANTARA, Kyriaki TSALKITZI, Ariane BIQUAND, Armelle BOHINEUST
Estimating the term…
The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease
A modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease.
Dependencies are inferred from the claim text.